Active, not recruitingPhase 2NCT05103358
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Studying GRFoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Aadi Bioscience, Inc.
- Intervention
- nab-sirolimus(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2022 – 2024
Study locations (20)
- Alabama Oncology, Birmingham, Alabama, United States
- Southern Cancer Center, Mobile, Alabama, United States
- Arizona Oncology Associates, Goodyear, Arizona, United States
- Honor Health, Phoenix, Arizona, United States
- Arizona Oncology Associates, Prescott Valley, Arizona, United States
- Yuma Regional Medical Center, Yuma, Arizona, United States
- PCR Oncology, Arroyo Grande, California, United States
- Nextgen Oncology, Beverly Hills, California, United States
- City of Hope, Duarte, California, United States
- Providence Medical Foundation (Fullerton), Fullerton, California, United States
- MemorialCare, Long Beach, California, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
- Providence Medical Foundation (Napa), Napa, California, United States
- Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05103358 on ClinicalTrials.gov